Background/aim: Critical coronavirus disease 2019 (COVID-19) is a rare but devastating complication of SARS-CoV-2 Omicron variant infection in children and adolescents. This study aimed to assess the risk factors for, and evaluate the vaccine effectiveness against, critical COVID-19 during the 2022 Omicron Surge in Taiwan.
Methods: We retrospectively enrolled 41 pediatric patients with critical COVID-19 (which required mechanical ventilation, inotropic agents, extracorporeal membrane oxygenator, or resulting in in-hospital death) and 793 with non-critical COVID-19 who were hospitalized at National Taiwan University Children Hospital during the 2022 Omicron Surge.